VOICE trial's disappointing result poses big questions for PrEP

Gus Cairns
Published: 04 March 2013
Jeanne Marrazzo discusses results of the VOICE study at CROI 2013. © Liz Highleyman / hivandhepatitis.com

The failure of one of the largest trials yet conducted of HIV drug-based prevention methods poses questions for how to turn vaginal microbicides and oral pre-exposure prophylaxis (PrEP) into methods people can actually use, the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) in Atlanta heard today.

The VOICE trial randomised 5029 women from three sites in South Africa, two in Zimbabwe and one in Uganda, although Durban in South Africa, with 3110 enrolled, provided more than half the participants. The women were randomised to use one of three prevention methods or two placebos (dummy methods):

  • daily Truvada (tenofovir plus emtricitabine) as PrEP;
  • daily tenofovir as PrEP;
  • a daily placebo pill looking like Truvada;
  • a tenofovir-containing gel, similar to that used in the CAPRISA 004 study, to be used as a vaginal microbicide;
  • an inert gel as a placebo microbicide.

The tenofovir oral PrEP arm, and the tenofovir vaginal gel and placebo arms of the trial were stopped due to futility in September and November 2011 respectively. ('Futility' means that the trial's data and safety monitoring board, which sees who is receiving treatment and who is receiving placebo, realised that there was no possibility that continuing the trial would produce a positive result.) The Truvada PrEP and placebo-pill arms, however, were continued.

But the conference heard today that Truvada had also not proven effective in preventing HIV and that therefore all three methods had proved no better than placebo.

Results: infections

This was a group of relatively young (average age 25) and largely unmarried (79% single) women. Retention – keeping trial subjects attending appointments – was good, with only 9% dropping out of the study.

Self-reported condom use at last vaginal sex was very high, at 85%, but needs to be regarded with a degree of scepticism given the extreme disconnect (see below) between self-reported and actual adherence. Quite a high proportion of women (17%) reported anal sex in the last three months.

During the trial 334 of the women tested HIV positive, but 22 of them turned out to have entered the trial while actually having been infected with HIV very shortly beforehand and so not testing HIV antibody positive. This means 312, or 6.2% of participants became infected during the trial, which translates into an annual incidence rate (infection rate per year) of 5.7%, with strong geographical variance by site from 0.8% to 9.9%.

None of the three prevention methods resulted in fewer HIV infections than placebo. In the women using the tenofovir-gel microbicide there were 15% fewer infections versus placebo, but this was not statistically significant. In the oral PrEP arms there were actually more infections in women taking PrEP compared to placebo. Women taking Truvada were 4% more likely and women taking tenofovir alone 49% more likely to become HIV positive than women taking placebo and in the latter case this was almost statistically significant (95% confidence interval 0.97-2.29, p = 0.07).

Results: adherence

Adherence to the pills or microbicide, according to two different methods of self-report, was 90%. However analysis of drug levels in the blood and in the case of the microbicide in vaginal fluids showed a very different story, and one that is starting to be familiar in PrEP and microbicide studies: only 28-29% of women taking tenofovir or Truvada PrEP had measurable drug levels in their blood, and only 22% of women using tenofovir microbicide.

The assays used could detect whether drug had been taken in the last two days on oral PrEP, and used in the last three days in the case of microbicide gel, so some may possibly have used PrEP or microbicide some time since the previous trial visit, but 50 to 58% of women, depending on which group they were in, had no detectable drug in their blood at any trial visit.

Women who were married, were aged over 25, or who had a primary partner aged over 28, were more likely to have detectable drug levels. In particular, married women were 2.6 times more likely to have detectable drug.  

Married women were also very considerably less likely to acquire HIV than unmarried women: annual incidence in married women in South Africa was 0.9%, compared with 7.5% in unmarried women. Women over 25 were half as likely to acquire HIV as women under 25 (annual incidence in South African women were 4.7% and 8.7% respectively).

These results seem to back up what was found in the similarly ineffective FEM-PrEP trial and in a recent pilot trial of PrEP in young gay men: being young seems to make it particularly difficult to adhere to these biomedical prevention methods and, as the investigators comment, suggests that "products that are long-lasting and require minimal daily adherence may be more suitable for this population." They also called for more social research to determine which populations might benefit.

In addition, as an audience member commented, the benefits of joining a trial like VOICE in a resource-poor setting – health monitoring, condoms, the ability to talk about sex with a counsellor, and so on – may be so large as to make the disclosure of non-adherence, and of other lapses such as not using condoms, almost impossible in the perception of the participants.

Reference

Marrazzo J et al. Pre-exposure prophylaxis for HIV in women: daily oral tenofovir, oral tenofovir/emtricitabine or vaginal tenofovir gel in the VOICE study (MTN 003). 20th Conference on Retroviruses and Opportunistic Infections, Atlanta, abstract 26LB, 2013.

View abstract 26LB on the conference website.

A webcast of the session in which this research was presented, HIV prevention: ARV, counseling, contraception, and condoms, is available on the conference website.

E-atlas

South Africa

Find details of HIV services in South Africa, the latest news from the country, and a selection of resources from local organisations.

Find out more about South Africa >

Related news selected from other sources

More editors' picks on prEP >

NAM is partnering with gTt (Barcelona), GAT (Lisbon) and LILA (Como) to deliver the CROI 2013 bulletins, which have also been made possible thanks to support from Bristol-Myers Squibb. NAM’s wider conference news reporting services have been supported by Abbott, Boehringer Ingelheim, Janssen, Roche and ViiV Healthcare. The funders have no editorial control over the content of the materials.